TABLE 1.
Baseline Demographic and Clinical Characteristics
| Characteristic | No. of Patients (%) | ||
|---|---|---|---|
| AS, n = 143 | ST, n = 305 | Total, N = 488 a | |
| Age: Median (IQR: 25%, 75%), y | 65 (58, 72) | 62 (55, 70) | 63 (56, 71) |
| Sex: Men | 103 (72) | 217 (71) | 320 (71) |
| Ethnicity: White | 131 (92) | 249 (82) | 380 (85) |
| ECOG PS b | |||
| 0 | 76 (53) | 109 (36) | 185 (41) |
| 1 | 43 (30) | 120 (39) | 163 (36) |
| 2 | 3 (2) | 37 (12) | 40 (9) |
| 3 | 1 (1) | 10 (3) | 11 (3) |
| Missing | 20 (14) | 29 (10) | 49 (11) |
| Histology type: Clear cell | 125 (87) | 232 (76) | 357 (80) |
| No. of metastatic sites b | |||
| 1 | 99 (69) | 175 (57) | 274 (61) |
| 2 | 33 (23) | 79 (26) | 112 (25) |
| ≥3 | 11 (8) | 51 (17) | 62 (14) |
| Site of metastasis | |||
| Liver | 11 (8) | 40 (13) | 51 (11) |
| Bone | 26 (18) | 83 (27) | 109 (24) |
| Brain/CNS | 6 (4) | 22 (7) | 28 (6) |
| Lung | 73 (51) | 173 (57) | 246 (55) |
| Lymph node | 32 (22) | 86 (28) | 118 (26) |
| Adrenal gland | 23 (16) | 25 (8) | 48 (11) |
| Prior nephrectomy | 83 (58) | 168 (55) | 251 (56) |
| Missing | 2 (1) | 9 (3) | 11 (3) |
| No. of IMDC risk factors b | |||
| 0, Favorable risk | 86 (60) | 42 (14) | 128 (29) |
| 1‐2, Intermediate risk | 54 (38) | 197 (65) | 251 (56) |
| ≥3, Poor risk | 3 (2) | 66 (22) | 69 (15) |
Abbreviations: AS, active surveillance; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic Renal Cell Database Consortium; IQR, interquartile range; ST, systemic therapy.
a
Forty‐one patients who were not classified as receiving AS or ST were not included. Other reason for "No Systemic Therapy Selected for Patient", see Figure 1.
b
P < .05.